Lapatinib
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="6" align="center"| | + | ! colspan="6" align="center"| VEGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
Revision as of 08:34, 6 December 2010
Pharmacokinetics
| VEGFR Inhibitor Pharmacokinetics [1][2][3][4] | |||||
|---|---|---|---|---|---|
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | |||
| Tmax (hr) | 4 | 8 | |||
| Cmax (ng/ml) | 115 | 24.6 | |||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | |||
| Protein Binding (%) | 99 | 95 | |||
| T1/2 (hr) | 9.6 | 83 | |||
| AUC (ng/ml/hr) | 1429 | 1921 | |||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | |||
| Dosage (mg) | 100 | 50 | |||
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | |||
